

"Hetero Corporate", 7-2-A2, Industrial Estates, Sanath Nagar, Hyderabad - 500 018, A.P., INDIA.
Tel: 91-40-23704923/24/25, Fax: 91-40-23704926, 23714250
e-mail: contact@heterodrugs.com URL: http://www.heterodrugs.com

SAFETY DATA SHEET

	Section 1: Identification		
Section 1, Identification			
GHS Product identifier	Rosuvastatin calcium Tablets, 5 mg, 10 mg, 20mg		
	and 40mg		
Trade Name	Not applicable		
Other means of identification			
Synonyms	Rosuvastatin calcium, Finished product		
Recommended use	Medicinal Product.		
Manufacturer	Hetero Labs Limited, Unit V, Polepally, Jadcherla		
	Mahaboob Nagar-509 301, India.		
Distributor	Camber Pharmaceuticals, Inc, Piscatway, NJ		
	08854		
Section 2: Hazar	d(s) Identification		
Section 2, Hazard(s)identification			
Classified hazards			
Olacomod Hazardo	Exempt from requirements		
Label elements	Exempt from requirements		
Hazard statement	Exempt from requirements		
Environment			
Section 3: Composition/I	Section 3: Composition/Information on Ingredients		
Ingredients	CAS		
Ingredients Rosuvastatin calcium			
	CAS 147098-20-2		
Rosuvastatin calcium Lactose Monohydrate, USP/NF (Flowlac 100)			
Rosuvastatin calcium	147098-20-2 CAS-No.: 64044-51-5		
Rosuvastatin calcium Lactose Monohydrate, USP/NF (Flowlac 100)	147098-20-2		
Rosuvastatin calcium Lactose Monohydrate, USP/NF (Flowlac 100) Microcrystalline Cellulose, USP/NF (Avicel PH 102) Crospovidone, USP/NF (Kollidon CL)	147098-20-2 CAS-No.: 64044-51-5		
Rosuvastatin calcium Lactose Monohydrate, USP/NF (Flowlac 100) Microcrystalline Cellulose, USP/NF (Avicel PH 102)	147098-20-2 CAS-No.: 64044-51-5 9004-34-6 616-45-5		
Rosuvastatin calcium Lactose Monohydrate, USP/NF (Flowlac 100) Microcrystalline Cellulose, USP/NF (Avicel PH 102) Crospovidone, USP/NF (Kollidon CL) Hydroxypropyl Cellulose, USP/NF(Klucel EXF)	147098-20-2 CAS-No.: 64044-51-5 9004-34-6		
Rosuvastatin calcium Lactose Monohydrate, USP/NF (Flowlac 100) Microcrystalline Cellulose, USP/NF (Avicel PH 102) Crospovidone, USP/NF (Kollidon CL) Hydroxypropyl Cellulose, USP/NF(Klucel EXF) Sodium Bicarbonate, USP (Emprove)	147098-20-2 CAS-No.: 64044-51-5 9004-34-6 616-45-5		
Rosuvastatin calcium Lactose Monohydrate, USP/NF (Flowlac 100) Microcrystalline Cellulose, USP/NF (Avicel PH 102) Crospovidone, USP/NF (Kollidon CL) Hydroxypropyl Cellulose, USP/NF(Klucel EXF)	147098-20-2 CAS-No.: 64044-51-5 9004-34-6 616-45-5 9004-64-2 144-55-8		
Rosuvastatin calcium Lactose Monohydrate, USP/NF (Flowlac 100) Microcrystalline Cellulose, USP/NF (Avicel PH 102) Crospovidone, USP/NF (Kollidon CL) Hydroxypropyl Cellulose, USP/NF(Klucel EXF) Sodium Bicarbonate, USP (Emprove) Talc, USP (Talc Luzenac Pharma)	147098-20-2 CAS-No.: 64044-51-5 9004-34-6 616-45-5 9004-64-2		
Rosuvastatin calcium Lactose Monohydrate, USP/NF (Flowlac 100) Microcrystalline Cellulose, USP/NF (Avicel PH 102) Crospovidone, USP/NF (Kollidon CL) Hydroxypropyl Cellulose, USP/NF(Klucel EXF) Sodium Bicarbonate, USP (Emprove)	147098-20-2 CAS-No.: 64044-51-5 9004-34-6 616-45-5 9004-64-2 144-55-8 14807-96-6		
Rosuvastatin calcium Lactose Monohydrate, USP/NF (Flowlac 100) Microcrystalline Cellulose, USP/NF (Avicel PH 102) Crospovidone, USP/NF (Kollidon CL) Hydroxypropyl Cellulose, USP/NF(Klucel EXF) Sodium Bicarbonate, USP (Emprove) Talc, USP (Talc Luzenac Pharma)	147098-20-2 CAS-No.: 64044-51-5 9004-34-6 616-45-5 9004-64-2 144-55-8		



Inhalation	Move to fresh air. If breathing is difficult, trained
	personnel should give oxygen. Call a physician if
	symptoms develop or persist. Under normal
	conditions of intended use, this material is not expected to be an inhalation hazard.
	Immediately flush skin with plenty of water. Take off
Skin Contact	contaminated clothing and wash before reuse. Get
	medical attention if symptoms occur.
Fire Company	Rinse thoroughly with plenty of water for at least 15
Eye Contact	minutes and consult a physician.
Ingestion	If swallowed, rinse mouth with water (only if the
ingestion	person is conscious). If ingestion of a large amount
	does occur, call a poison control center immediately.
	Do not induce vomiting without advice from poison control center.
Most important symptoms/effects, acute and delay	
Indication of immediate	No specific antidotes are recommended. Treat according to locally accepted protocols. For additional guidance, refer to
medical attention and special	the current prescribing information or to the local poison
treatment needed	control information center.
General information	In the case of accident or if you feel unwell, seek
	medical advice Immediately. Ensure that medical
	personnel are aware of the material(s) involved, and
	take precautions to protect themselves.
Section 5: Fire-F	ighting Measures
Section 5, Fire-fighting measures	
Suitable Extinguishing Media	Water, Foam, Dry chemical powder, carbon dioxide.
Unsuitable Extinguishing Media	Not available
Specific hazards arising from During fire, gases	
hazardous to health may be formed.	During fire, gases hazardous to health may be formed.
the chemical	iormea.
Special protective equipment and precautions for	Self-contained breathing apparatus and full protective
firefighters	clothing must be worn in case of fire.
- In only into its	
special fire fighting procedures	Move containers from fire area if you can do so
	without risk. Use standard firefighting procedures and consider the
Specific methods	hazards of other involved materials.
Section 6: Accidenta	al Release Measures
Section 6, Accidental release measures	
Personal precautions, protective equipment and	Keep unnecessary personnel away. Keep people away
	from and upwind of spill/leak. Wear appropriate protective
emergency procedures	equipment and clothing during clean-up. Ensure adequate
	ventilation. Local authorities should be advised if
	significant spillages cannot be contained.
Environmental pressutions	Avoid release to the environment. Inform
Environmental precautions	appropriate managerial or supervisory personnel of
	all environmental releases. Prevent further leakage



	or spillage if safe to do so	. Avoid discharge into	
	drains, water courses or onto the ground.		
Methods and materials for	This material is classified as a water pollutant und		
containment and cleaning up	the Clean Water Act and	should be prevented from	
3 .P	contaminating soil or from	entering sewage and	
	drainage systems which le	ead to waterways.	
	Stop the flow of material,	f this is without risk.	
	Following product recover	y, flush area with water for	
	waste disposal.		
Section 7: Han	dling and Storage		
Section 7, Handling and storage			
Handling	Provide adequate ventilati environment. Avoid prolonge		
Conditions for safe storage,		s Store at 20 to 25°C (68 to	
including any incompatibilities	77° F) [see USP Controlle	ed Room Temperature].	
Section 8: Exposure Controls/Personal Protection			
Section 8, Exposure controls/personal protection			
Components		rpe	
	ACGIH TLV	OSHA PEL	
Lactose Monohydrate, USP/NF (Flowlac 100)	AGW BGW	Not applicable	
(Nowide 100)	General 1.25 mg/m³ alveolar fraction		
	Dust limit 10 mg/m³ respiratory fraction		
Microcrystalline Cellulose, USP/NF (Avicel PH 102)	10 mg/m3 (TWA)	15 mg/m3 (PEL) (total dust) 5 mg/m3 (PEL) (respirable fraction of dust)	
Crospovidone, USP/NF (Kollidon CL)	No occupational exposure limits known.	No occupational exposure limits known.	
Hydroxypropyl Cellulose, USP/NF (Klucel EXF)	Contains no substances with occupational exposure limit values.	Contains no substances with occupational exposure limit values.	
Sodium Bicarbonate, USP (Emprove)	Contains no substances with occupational exposure limit values.	Contains no substances with occupational exposure limit values.	
Talc, USP (Talc Luzenac Pharma)	Not available	Not available	
Magnasium Characta LICD NE			
Magnesium Stearate USP-NF (LIGAMED MF-2-V)	Not available	Not available	



0		<u> </u>	
Opadry Yellow 32K520068, IHS	Not available	Not available	
Opadry II Pink 32K540033, IHS	Not available	Not available	
Appropriate engineering Controls	General ventilation normally adequate.		
Individual protection measures, such as personal	protective equipment		
Eye/face protection	Not normally needed. If co	ontact is likely, safety	
	glasses with side shields a	are recommended.	
Skin protection Hand protection	Not normally needed. For prolonged or repeated		
	skin contact use suitable p	protective gloves.	
Respiratory protection	No personal respiratory pr	rotective equipment	
	normally required. Use a f	• •	
	respirator if there is a risk	·	
	at levels exceeding the ex		
Hygiene considerations	Always observe good pers		
	such as washing after har before eating, drinking, an	_	
	wash work clothing and pr		
	remove contaminants. For	• •	
		guidance from a qualified	
	environment, health and s		
Section 9: Physical an	d Chemical Propertie	es	
Section 9, Physical and chemical properties			
Physical State	Solid		
Form	Tablets		
Colour	Light Yellow- 5mg, Light 40 mg	pink-10mg, 20 mg and	
Odor	Not available		
Description	Rosuvastatin calcium Ta	ablets, 5 mg	
	Light yellow to yellow, rou	nd, bevel edged biconvex	
	film coated tablets deboss	sed with 'H' on one side	
	and 'R3' on the other side		
	Bottle of 90 Tablets	(NDC 31722-882-90)	
	Blister pack of 100 (10×10)) Unit dose tablets	



Inhalation

HETERO LABS LIMITED

"Hetero Corporate", 7-2-A2, Industrial Estates, Sanath Nagar, Hyderabad - 500 018. A.P., INDIA.

Tel: 91-40-23704923/24/25, Fax: 91-40-23704926, 23714250

e-mail: contact@heterodrugs.com URL: http://www.heterodrugs.com

(NDC 31722-882-31)
Rosuvastatin calcium Tablets, 10 mg
Light pink to pink, round, bevel edged biconvex film
-coated tablets debossed with 'H' on one side and
'R4' on the other side.
Bottle of 90 Tablets (NDC 31722-883-90)
Blister pack of 100 (10×10) Unit dose tablets
(NDC 31722-883-31)
Rosuvastatin calcium Tablets, 20 mg
Light pink to pink, round, bevel edged biconvex film
coated tablets de bossed with 'H' on one side and
'R5' on the other side.
Bottle of 90 Tablets (NDC 31722-884-90)
Blister pack of 100 (10×10) Unit dose tablets
(NDC 31722-884-31)
Rosuvastatin calcium Tablets, 40 mg
Light pink to pink, oval, bevel edged biconvex film
coated tablets debossed with 'H' on one side and
'R6' on the other side.
Bottle of 30 Tablets (NDC 31722-885-30)
Blister pack of 100 (10×10) Unit dose tablets
(NDC 31722-885-31)
1

Section 10: Stability and Reactivity Section 10, Stability and reactivity Reactivity The product is stable and non-reactive under normal conditions of use, storage and transport. **Chemical stability** Material is stable under normal conditions. Reactions Hazardous polymerization does not occur. Conditions to avoid Contact with incompatible materials Incompatible materials Strong oxidizing agents. **Hazardous decomposition** None known. Irritating and/or toxic fumes and gases may be emitted upon the product's decomposition products **Section 11: Toxicological Information** Information on likely routes of exposure

Under normal conditions of intended use, this

material is not expected to be an inhalation hazard.



Skin contact		He	alth injuries are no	ot known or expected under
OKIII GOIRIGGE		normal use.		
Eye contact				
Lyc contact		Health injuries are not known or expected under		
		normal use.		
Ingestion		He	alth injuries are no	ot known or expected under
		normal use. However, ingestion is not likely to be a		
,		primary route of occupational exposure.		
Acute toxicity :				
Components	LD50 oral		LD50 dermal	LD50 inhalation
Lactose Monohydrate, USP/NF (Flowlac 100)	>10 g/kg -Rat		Not available	Not available
Microcrystalline Cellulose,	>5,000 mg/kg-Rat		> 2,000 mg/kg	> 5.05 mg/l (4 h) (rat)
USP/NF (Avicel PH 102)			(rabbit)	
Crospovidone, USP/NF (Kollidon CL)	> 2,000 mg/kg-Rat	İ	Not available	> 5.2 mg/l -rat
Hydroxypropyl Cellulose, USP/NF (Klucel EXF)	> 10 g/kg-Rat		Not available	Not available
Sodium Bicarbonate, USP (Emprove)	4,220 mg/kg -Rat		Not available	Not available
Talc, USP (Talc Luzenac Pharma)	Not available		Not available	Not available
Magnesium Stearate USP-NF (LIGAMED MF-2-V)	Not available		Not available	Not available
Opadry Yellow 32K520068, IHS			Not available	Not available
Opadry II Pink 32K540033, IHS	23854 mg/kg		Not available	Not available
Skin corrosion/irritation		Health injuries are not known or expected under normal use		
Respiratory or skin sensitization	n	No studies have been conducted		
Germ cell mutagenicity		Health injuries are not known or expected under normal use		
Carcinogenicity		Rosuvastatin, the active substance in this product,		
-		produced carcinogenic effects in a lifetime study in		
		mice. These effects are linked only to high doses of		
		this substance; lower doses did not cause this		
		adverse effect.		
Reproductive toxicity		Components in this product have been shown to		
Top. Sauditive textolly		cause birth defects and reproductive disorders in		
		laboratory animals. These effects are linked only to		
		high doses of this substance; low doses did not		
		produce this adverse effect.		
		produce this adverse effect.		



"Hetero Corporate", 7-2-A2, Industrial Estates, Sanath Nagar, Hyderabad - 500 018, A.P., INDIA.
Tel: 91-40-23704923/24/25, Fax: 91-40-23704926, 23714250
e-mail: contact@heterodrugs.com URL: http://www.heterodrugs.com

Effects on Fertility:	Other measures of fertility
Specific target organ toxicity - single exposure (GHS)	no data available
Specific target organ toxicity - repeated exposure (GHS)	May cause damage to organs through prolonged or repeated exposure.
Aspiration hazard	no data available

Section 12: Ecological Information

Toxicity: Contains a substance which causes risk of hazardous effects to the environment.

Components	Toxicity to algae	Toxicity to	Toxicity to	Daphnia
		fish	microorganisms	Magna(Water
				flea)
Lactose Monohydrate, USP/NF (Flowlac 100)	Not available	Not available	Not available	Not available
Microcrystalline Cellulose, USP/NF (Avicel PH 102)	Not available	Not available	Not available	48-hour LC ₅₀ > 100%, saturated solution, NOEC = 100% (daphnia)
Crospovidone, USP/NF (Kollidon CL)	Not available	LC50 (96 h) > 10,000 mg/l,	Not available	Not available
Hydroxypropyl Cellulose, USP/NF (Klucel EXF)	Not available	> 100 mg/l Exposure time: 96 h	Not available	Not available
Sodium Bicarbonate, USP (Emprove)	Not available	7,550 mg/l; 96 h	Not available	2,350 mg/l; 48 h
Talc, USP (Talc Luzenac Pharma)	Not available	Not available	Not available	Not available
Magnesium Stearate USP-NF (LIGAMED MF-2-V)	Not available	Not available	Not available	Not available
Opadry Yellow 32K520068, IHS	Not available	Not available	Not available	Not available
Opadry II Pink 32K540033, IHS	Not available	Not available	Not available	Not available

Section 13: Disposal Considerations

Waste treatment methods

Disposal instructions	Collect and reclaim or dispose in sealed containers
	at licensed waste disposal site. Do not discharge
	into drains, water Courses or onto the ground.
	Dispose in accordance with all applicable
	regulations.



Local disposal regulations	Dispose in accordance with all applicable	
	regulations.	
Hazardous waste code	The waste code should be assigned in discussion	
	between the user, the producer and the waste	
	disposal company.	
Waste from residues I unused	Dispose of in accordance with local regulations.	
	Empty containers or liners may retain some product	
	residues. This material and its container must be	
	disposed of in a safe manner Avoid discharge into	
	water courses or onto the ground. Products.	
Contaminated packaging	Since emptied containers may retain product	
	residue, follow label warnings even after container is	
	emptied. Empty containers should be taken to an	
	approved waste handling site for recycling or	
	disposal.	
Section 14: Tra	nsport Information	
DOT	•	
UN-Number Proper shipping name Hazard class Reportable quantity Description Emergency response guide Number	Not applicable	
IATA		
UN-Number Proper shipping name Hazard class Description	Not applicable	
UN-Number	Not an alterial	
Proper shipping name Hazard class Reportable quantity Description Emergency response guide Number	Not applicable	
	ulatory Information	
U.S State regulations		
California Proposition 65: This product does not content any proposition 65 chemicals		
• • •	ther Information	
Section 16, Other information		
Issue Date : 10-21-2016		



"Hetero Corporate", 7-2-A2, Industrial Estates, Sanath Nagar, Hyderabad - 500 018. A.P., INDIA.

Tel: 91-40-23704923/24/25, Fax: 91-40-23704926, 23714250

e-mail: contact@heterodrugs.com URL: http://www.heterodrugs.com

Version: 00

Further information

Revision date: New issue Revision note: New issue

The information and recommendations in this safety data sheet are, to the best of our knowledge, accurate as of the date of issue. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.

Hetero Labs Limited shall not be held liable for any damage resulting from handling or from contact with the above product. Hetero Labs Limited reserves the right to revise this SDS.